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A B S T R A C T   
The insulin-like growth factor (IGF) system is a critical regulator of growth, especially during fetal development, 
while also playing a central role in metabolic homeostasis. Endocrine disruptors (EDs) are ubiquitous compounds 
able to interfere with hormone action and impact human health. For example, exposure to EDs is associated with 
decreased birthweight and increased incidence of metabolic disorders. Therefore, the IGF system is a potential 
target for endocrine disruption. This review summarises the state of the science regarding effects of exposure to 
major classes of endocrine disruptors (dioxins and dioxin-like compounds, polycyclic aromatic hydrocarbons, 
polybrominated diphenyl ethers, phthalates, perfluoroalkyl substances and bisphenol A) on the IGF system. 
Evidence from both experimental models (in vitro and in vivo) and epidemiological studies is presented. In 
addition, possible molecular mechanisms of action and effects on methylation are discussed. There is a large body 
of evidence supporting the link between dioxins and dioxin-like compounds and IGF disruption, but mixed 
findings have been reported in human studies. On the other hand, although only a few animal studies have 
investigated the effects of phthalates on the IGF system, their negative association with IGF levels and 
methylation status has been more consistently reported in humans. For polybrominated diphenyl ethers, per-
fluoroalkyl substances and bisphenol A the evidence is still limited. Despite a lack of studies for some ED classes 
linking ED exposure to changes in IGF levels, and the need for further research to improve reproducibility and 
determine the degree of risk posed by EDs to the IGF system, this is clearly an area of concern.   
1. Introduction 
1.1. Insulin-like growth factor system in physiology 
The insulin-like growth factor (IGF) system is a highly conserved 
signalling pathway. The IGF system is involved in the regulation of 
growth, proliferation and differentiation in most cell types and acts in an 
endocrine, paracrine and autocrine fashion. The system includes two 
growth factors, insulin-like growth factor 1 (IGF-1) and insulin-like 
growth factor 2 (IGF-2), two receptors, IGF-1 receptor (IGF-1R) and 
IGF-2 receptor (IGF-2R), and IGF binding proteins (IGFBPs) (Fig. 1). IGF- 
1 and IGF-2 are widely expressed peptides with the liver being the main 
site of production (Hill, 1990; Rajpathak et al., 2009). The peptides are 
structurally very similar and they also share substantial sequence ho-
mology to proinsulin (50%) (Daughaday et al., 1989). IGFs exert their 
endocrine functions by binding to two cell surface receptors, which are 
expressed in almost all cell types, with different levels of affinity (Funk 
et al., 1992; Kineman et al., 2018). IGF-1R binds IGF-1 with the highest 
affinity, whereas IGF-2R binds IGF-2 with the highest affinity (Laviola 
et al., 2007). Furthermore, insulin can also bind IGF-1R and, at the same 
time, IGFs can interact with the insulin receptor (IR), but with much 
lower affinity compared to the main ligands (Andersen et al., 2017; 
Laviola et al., 2007). IGF-2R is considered an inhibitor receptor as IGF-2 
binding to this receptor leads to IGF-2 degradation and is not associated 
with any intracellular signalling (Scott and Weiss, 2000). 
Insulin-like growth factor binding proteins (IGFBPs) are a family of 
carrier proteins acting as major modulators of IGF activity. The affinity 
of IGFs for IGFBPs is higher than for the IGF-1R, therefore, in the 
extracellular environment, most IGFs are bound to IGFBPs, with IGFBP- 
3 being the most prevalent in human serum (Bach, 2018a). By binding 
IGFs, IGFBPs decrease IGF bioavailability and extend their half-life, also 
facilitating their transport through body compartments (Ranke and Wit, 
2018). IGFBPs are cleaved by specific proteases, including the 
pregnancy-associated plasma protein A family, and cleavage reduces 
their affinities for IGFs (Bach, 2018b; Clemmons, 2018). 
IGF signalling is involved in a wide variety of fundamental processes, 
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with two major domains: growth and metabolic regulation. IGFs 
mediate growth-promoting actions in several organs, during the 
different stages of development (Murphy et al., 2006). IGF-1 mediates 
most of the growth-promoting actions of growth hormone (GH), forming 
a system which is commonly referred to as the GH-IGF axis (Florini et al., 
1996). According to the original somatomedin hypothesis, GH secreted 
by the pituitary, binds to GH receptor (GHR), this stimulates liver pro-
duction of IGF-1, which then acts peripherally in an endocrine manner 
(Daughaday et al., 1989). In turn, circulating IGF-1 is responsible for the 
negative feedback inhibition on hypothalamic/pituitary regulation of 
GH secretion (Kineman et al., 2018). The GH/IGF system has been 
implicated in establishing sexually dimorphic liver functions, at least in 
rodent models (Adams et al., 2015; Ohlsson et al., 2009). Indeed, 
liver-specific inactivation of IGF-1 feminises GH-regulated liver func-
tions (Wallenius et al., 2001). Interestingly, sexual dimorphism in IGF-2 
action during fetal life has been shown in animal models, with the IGF 
system in males being more sensitive to exogenous IGF-2 administration 
(White et al., 2018). The hypothesis has been challenged by subsequent 
research, as it is now well established that GH actions are not always 
mediated by IGFs and that, on the other hand, IGFs are not only regu-
lated by GH and also have autocrine and paracrine modes of action 
(Ohlsson et al., 2009). Although the liver is the major site of production, 
IGF-1 is also locally produced by the majority of cell types, which also 
express IGF-1R and IGF-2R (Ferry et al., 1999). For example, both IGF-1 
and IGF-2 are also produced by the human placenta, where they act as 
local growth regulators (Fant et al., 1986; Han et al., 1996). It is difficult 
to fully differentiate the roles played by circulating IGFs from locally 
produced IGFs, although great progress has been made using 
tissue-specific inactivation studies in animal models (Kineman et al., 
2018). 
In humans, IGF-2 is the major growth factor during fetal life and its 
concentration is five to six times higher than IGF-1 in the fetus, with 
levels progressively increasing throughout pregnancy (Fisher, 2016). 
IGF-1 exerts its role mainly during childhood, with levels peaking 
around puberty, and subsequently starting to decline (Löfqvist et al., 
2001). IGF-1 levels in cord blood are positively associated with birth-
weight (Geary et al., 2003; Vatten et al., 2002). IGF-2 cord blood levels 
are only weakly related to birth size, largely because IGF-2 exerts its 
major growth-stimulating effect during the first part of gestation (Fisher, 
2016). The critical role played by IGFs during development is shown by 
typical phenotypes exhibited by knockout mice models. Mice lacking 
IGF-1, IGF-2 or IGF-1R show intrauterine growth restriction, whereas 
IGF-2R knockout fetal mice are overweight, supporting the negative 
growth-modulating action of this receptor (Baker et al., 1993; DeChiara 
et al., 1990; Liu et al., 1993). In humans, mutations in IGF-1 and IGF-1R 
genes are associated with growth retardation (Abuzzahab et al., 2003; 
Woods et al., 1996). In animal models, IGF-1 stimulates longitudinal 
bone growth and it is involved in regulating liver, kidney and prostate 
size (Ohlsson et al., 2009). 
IGFs have roles in metabolic regulation and disease and have been 
recently reviewed (Haywood et al., 2019). Given the large similarities 
between IGFs and insulin, it is not surprising that their actions are 
partially overlapping. The IGF-system is directly involved in regulating 
glucose homeostasis, given its insulin-like effect (Rajpathak et al., 
2009). IGF-1 can act independently of insulin or enhance insulin action, 
as they share part of the same signalling pathway. For instance, once 
IGF-1 binds IGF-1R, autophosphorylation occurs, providing docking 
sites for the insulin receptor substrates, activating downstream signal-
ling which results in increased glucose uptake (Haywood et al., 2019). In 
animals, IGF-1 is of importance for normal carbohydrate metabolism, 
with IGF-1 acting in concert with insulin to lower glycemia (Sjögren 
et al., 2001). Similarly, roles in lipid metabolism and fat mass 
Fig. 1. Components and main functions of the IGF system. Free IGF-1 and IGF-2 can bind to their receptors (IGF-1R, IGF-2R). IGF binding proteins (IGFBP1-7) 
regulate IGFs bioavailability. IGF-1R is a tyrosine kinase which mediates actions of IGFs. IGF-2R is an inhibitory receptor, as it directs IGF-2 to lysosomes for 
degradation. IGFs can also bind insulin receptor (IR). 
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development have also been suggested (Ohlsson et al., 2009). IGF-1 
levels are altered in adults with cardiovascular disease (Obradovic 
et al., 2019; Ren and Anversa, 2015), obesity (Berryman et al., 2013), 
insulin resistance (Cubbon et al., 2016), and type 2 diabetes (Shi et al., 
2018). IGF-1 is also involved in regulating peripheral vascular resis-
tance, sodium retention and insulin sensitivity (Ohlsson et al., 2009). 
Among the other roles, IGF-1 is involved in regulating ovarian function, 
particularly in follicular selection. Indeed, targeted disruption of the 
IGF-1 gene in mice causes infertility due to anovulation in females and a 
decrease in testosterone in males (Baker et al., 1996). Furthermore, IGF- 
1 is implicated in brain development, maturation and neuroplasticity 
(Dyer et al., 2016). IGF-1 and IGF-2 also play a role for cell trans-
formation in several cancer types (Bach, 2018b). 
Besides its direct interaction with GH, the IGF system is involved in 
multiple endocrine pathways. For example, estrogen increases hepatic 
IGF-1 production (Venken et al., 2005) while locally, estrogen-mediated 
regulation of IGF-1 is involved in uterine growth (Hewitt et al., 2010). 
Inactivation of IGF-1R in granulosa cells leads to decreased cell differ-
entiation, proliferation and estrogen production and, hence, to infertility 
(Baumgarten et al., 2017). Furthermore, combined IGF1R/INSR 
knockout resulted in decreased glucocorticoid and testosterone pro-
duction, associated with impaired testicular and adrenal cortical 
development (Neirijnck et al., 2018). 
The main role of IGBFPs is to modulate IGF actions (Rajaram et al., 
1997). IGFBP expression is widespread and it has been suggested that 
they might play a tissue-specific role. The liver is the main site of pro-
duction of most IGFBPs, but proteins have been found in a number of 
organs, including uteri, ovaries, smooth muscles and heart (Jones and 
Clemmons, 1995). Furthermore, in some circumstances, IGFBPs poten-
tiate IGF action and also have IGF-independent actions (Bach, 2018b). 
IGFBP-1 is the most abundant IGFBP in fetal tissues (Pannier et al., 
1994) and is the major regulator of IGF actions during pregnancy 
(Murphy et al., 2006). Over-expression of IGFBP1, in transgenic mice 
results in a transient decrease in mid-gestation fetal growth (Crossey 
et al., 2002). Elevated circulating IGFBP-1 levels have been linked with 
low birthweight, possibly by reducing IGF bioavailability (Tisi et al., 
2005; Vatten et al., 2002; Wang et al., 1991). The main interest in 
IGFBP-1 is that its production is inversely regulated by insulin (Brismar 
et al., 1994). On the other hand, IGFBP-3 is the main serum carrier of 
IGF-1 (Jones and Clemmons, 1995). Although other IGFBPs have been 
less extensively investigated, a large body of evidence, recently 
reviewed in (Bach, 2018a; Clemmons, 2018), supports their role in 
several disease processes, particularly metabolic-related diseases and 
cancer progression. 
1.2. Endocrine disruptors impact on growth and metabolism 
Endocrine disruptors (EDs) include a wide variety of compounds able 
to interfere with hormone action and to negatively impact human and 
animal health (Gore et al., 2015). For instance, exposure to EDs has been 
associated with reproductive disorders, cognitive deficits, and various 
cancers (Gore et al., 2015; Heindel et al., 2015; La Merrill et al., 2020). 
Furthermore, many of these environmental contaminants can directly 
impact metabolic organs/tissues, such as the liver, pancreas and adipose 
tissue and are thus defined metabolism-disrupting chemicals or obes-
ogens (Heindel et al., 2017). Exposure to these EDs has been linked to 
development of obesity, metabolic syndrome, type-2 diabetes and fatty 
liver disease (Heindel et al., 2015). 
It has been suggested that EDs can also affect growth, therefore many 
researchers have investigated the relationship between ED exposure and 
birth weight (Street and Bernasconi, 2020). Exposure to many EDs has 
been associated with low birthweight, altered anthropometric measures 
and rapid catch-up growth during childhood (Buck Louis et al., 2018; Fei 
et al., 2007; Kishi et al., 2017; Zheng et al., 2016). In a large meta- 
analysis, maternal occupational exposure to at least one ED group 
(such as polycyclic aromatic hydrocarbons, polychlorinated organic 
compounds, phthalates and bisphenol A among the others) was linked to 
an increased risk of having a low-birth weight newborn (Birks et al., 
2016). In another study based on 7 different European cohorts, prenatal 
exposure to polychlorinated biphenyl 153 (PCB-153) and perfluorinated 
compounds (PFAS) was associated with increased risk of having small 
for gestational age newborns (Govarts et al., 2018). 
The IGF system plays a critical role in ensuring appropriate growth 
and in regulating metabolic homeostasis. We have, therefore, hypoth-
esised that impact of exposure to EDs on the IGF system might represent 
a potential mechanism behind well-described adverse outcomes of ED 
exposure such as growth restriction and metabolic syndrome. 
In the present review, we summarize current evidence of the impact 
of several classes of EDs on the IGF system. We focused on major classes 
of EDs including dioxins and dioxin-like compounds, polycyclic aro-
matic hydrocarbons (PAHs), polybrominated biphenyls ethers (PBDEs), 
phthalates, perfluoroalkyl substances (PFAS) and bisphenol A (BPA) 
(Fig. 2). In vitro and in vivo studies performed on mammals are pre-
sented. Studies performed in fish models are summarised in Supple-
mentary Table 1 but are not included in the body of the review. 
Epidemiological studies are also reported, and current knowledge gaps 
discussed. 
2. Effects of EDs on the IGF system 
2.1. Dioxins and dioxin-like compounds 
Dioxins and dioxin-like compounds are highly persistent organic 
pollutants. They include dioxins, polychlorinated dibenzo-p-dioxins 
(PCDDs); furans, polychlorinated dibenzofurans (PCDFs); and poly-
chlorinated/polybrominated biphenyls (PCBs/PBBs). PCDDs and PCDFs 
are by-products of incineration and organic synthesis procedures, 
whereas PCBs are mostly man-made compounds with many industrial 
and commercial applications (Giesy and Kannan, 1998; Gore et al., 
2015; White and Birnbaum, 2009). 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
(TCDD) is a polychlorinated dibenzo-p-dioxin and is the most potent 
compound of this class of chemicals. Effects of exposure to TCDD on the 
IGF pathway have been widely investigated in several cell lines (mainly 
human breast cancer and hepatocarcinoma lines) and animal models 
(Tables 1 and 2). In contrast, evidence for other compounds of the group 
is limited to a few animal studies (Table 3). 
In the human breast cancer cell lines, MCF-7 and T47-D, TCDD 
inhibited IGF-1 and IGF-2 mediated cell proliferation (Liu et al., 1992; 
Salisbury et al., 2013). TCDD exposure did not change IGF-1R transcript 
levels, but resulted in a decreased number of IGF-1 induced binding sites 
in IGF-1R (Liu et al., 1992). The findings were not confirmed in other 
studies, although similar TCDD dose levels were employed (Tanaka 
et al., 2007; Tannheimer et al., 1998). In MCF-7 cells, IGF-1R up-regu-
lation following TCDD treatment was reported only in microarray ex-
periments but not confirmed by real-time PCR (Tanaka et al., 2007). In 
other studies TCDD treatment of MCF-7 cells induced IGFBP-3 and 
decreased IGFBP-5 expression (Tanaka et al., 2007; Widerak et al., 
2006). On the other hand, in an alternative mammary epithelial cell line 
(MCF-10A), TCDD induced cell proliferation and activated IGF-1 path-
ways, mimicking signalling through the IGF-1R, but only if cells were 
cultured under insulin-deficient conditions (Tannheimer et al., 1998). 
Such differences in cell line and culturing conditions (lack of insulin, 
which is known to interact with IGF pathway) might explain some of the 
differences in results reported in these studies. 
Given that the liver is one of the main organs of the IGF system, it is 
not surprising that hepatic in vitro models have been widely used to 
investigate TCDD effects. Several studies found a positive association 
between TCDD exposure and IGFBP-1 levels in the human hep-
atocarcinoma cell line HepG2, at both the transcript and protein level 
(Adachi et al., 2004; Marchand, 2004; Murray and Perdew, 2007). In 
this cell line, IGFBP-1 was among the top up-regulated genes following 
TCDD treatment (Adachi et al., 2004) and regulation of IGFBP-1 
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transcription by TCDD was dose-responsive (Murray and Perdew, 2007). 
TCDD-mediated induction of IGFBP-1 was also confirmed in cultured 
human hepatocytes (Marchand, 2004). Except for IGFBP-1, other ele-
ments of the system have been less extensively investigated and are not 
clearly affected by TCDD. TCDD did not affect IGF-1, IGF-2, IGF-1R, 
IGFBP-2 and IGFBP-4 expression in human cultured hepatocytes 
(Marchand, 2004). In another rat hepatoma cell line (5L), TCDD treat-
ment induced IGFBP-4 (IGFBP-1 to IGFBP-7), but the authors argue this 
is an artefact of the cell line generation process (Brandner et al., 2013). 
These are amongst the few in vitro studies which evaluated multiple 
elements of the IGF system. On the other hand, IGF-2 induction by TCDD 
was reported in the rat hepatoma cell line BRL-3A (Wang et al., 2011), 
which might indicate differential responses depending on the specific 
cell line. 
Detrimental effects associated with TCDD exposure during devel-
opment have been investigated in several studies. Most of the studies 
have focused on the effects on IGF-2/IGF-2R, considering its critical role 
during the prenatal period. Overall, a negative association between 
prenatal TCDD exposure and IGF-2 has been found in several organs 
(Ding et al., 2018; Ma et al., 2015; Wu et al., 2004; Zhang et al., 2019b), 
although one study reported opposite effects (Wang et al., 2011). In mice 
prenatally exposed to TCDD during the preimplantation stage only, a 
trend for a decrease in IGF-2 mRNA was found following whole-body 
analysis of embryos (Wu et al., 2004). In a transgenerational study, 
both F1 male mice prenatally exposed to a single dose of TCDD (10 μg/ 
kg body weight) on gestational day 15 (GD15) (direct prenatal TCDD 
exposure) and F3 male descendants (ancestral exposure) showed 
decreased placental IGF-2 (Ding et al., 2018). Similarly, prenatal expo-
sure to TCDD from GD8 to GD14 (0.5 μg/kg body weight/day) decreased 
intra-ovarian transcript levels of IGF-2 in adult female rats (Zhang et al., 
2019b). Prenatal exposure to TCDD (0.8 μg/kg body weight/day, GD8- 
GD14) also decreased IGF-2 expression at both transcript and protein 
levels in the adult livers of both F1 rats prenatally exposed to TCDD and 
theirs F3 descendants (Ma et al., 2015). This is in contrast with a pre-
vious study (single TCDD exposure on GD10 at 10 μg/kg body weight) in 
which increased IGF-2 in the fetal liver was found instead (although no 
changes reported in other organs such as kidney and skeleton) (Wang 
et al., 2011). The different dose levels and dose timings, as well as dif-
ferences in life stages when the IGF system was analysed will all 
contribute to the differences observed, although most reported 
decreased IGF system expression in some organs following TCDD 
exposure. The effects of in utero exposure to TCDD on IGF-2R was 
investigated only in male offspring. TCDD exposure increases IGF-2R 
transcript levels in sperm, whereas a decreased mRNA was reported in 
the liver and in the skeletal muscle (Somm et al., 2013). Female pups 
exposed to TCDD prenatally and during lactation, exhibited a decreased 
IGF-1 transcript level in the liver (Chaffin et al., 1996). Moreover, an 
upregulation of IGFBP-1 mRNA has been reported in the kidney of 
mouse pups exposed to TCDD during lactation (Yoshioka et al., 2014). 
Prenatal exposure to TCDD up-regulated IGFBP-6 in fetal rat calvaria 
(Guo et al., 2007), whereas IGFBP-5 was significantly upregulated in 
fetal brain, but downregulated in fetal liver and in calvaria of female 
pups (Tanaka et al., 2007). 
A few studies evaluated effects of TCDD administered to adult ani-
mals. In adult rats exposed to TCDD, both chronically or with a single 
large dose level, circulating IGF-1 levels significantly decreased 
(Croutch et al., 2005; Lindén et al., 2014). Moreover, TCDD treatment 
induced hepatic mRNA expression of IGFBP-1 (Minami et al., 2008). 
TCDD treatment in mice induced IGFBP-6 in the thymus and bone 
marrow, at both the transcriptional and protein level, with the finding 
confirmed in vitro using a thymoma cell line (EL-4) (Park et al., 2001; 
Park et al., 2003). TCDD is the most widely investigated chemical in 
terms of interaction with the IGF system. Overall, in cell models, the 
evidence strongly supports the TCDD effect of inducing IGFBP-1 up- 
regulation, which is of clear relevance as this protein is produced pri-
marily by hepatocytes in both rodents and humans (Jones and Clem-
mons, 1995). Moreover, low levels of IGF-1 and IGF-2 have been 
reported in several organs in animal studies following TCDD exposure, 
mainly during the prenatal period. 
The effects associated with administration of a range of PCBs have 
been evaluated in a few in vivo studies. Rats prenatally exposed to PCB- 
126 exhibited reduced circulating levels of both IGF-1 and IGF-2 
(Ahmed et al., 2018). PCB-95 administered to early-weaned male rats 
decreased IGF-1 serum concentration (Ahmed, 2013) and PCB-126 
lowered IGF-1 levels in adult rats (Ronis et al., 2020). PCB-126 and 
PCB-153 increased intestinal IGFBP-3 protein levels in a dose-response 
manner in a rat model of chronic exposure (Lee et al., 2000). These 
studies largely support the negative impact of these chemicals on IGF 
signalling, as shown by studies in which TCDD was administered. 
Several epidemiological studies have investigated the association 
between dioxin-like compounds and IGF-1 and IGFBP-3. The direction of 
effects varied across studies (Table 3). A cohort of mother-children pairs 
Fig. 2. Schematic representation of chemical classes (and a representative molecule) of endocrine disrupting chemicals impacting IGF system.  
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was recruited and followed up to assess the impact of prenatal exposure 
to dioxins and PCBs on growth and thyroid function in children (Su 
et al., 2015, 2010; Wang et al., 2005). Pregnant women were recruited 
and 17 polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/ 
PCDFs) and 12 dioxin-like PCB congeners (PCBs) were measured in their 
placentas. IGF-1 and IGFBP-3 levels were assessed in blood of their 
children at birth (n = 118) (Wang et al., 2005), at 2 (n = 70) and 5 years 
of age (n = 41) (Su et al., 2010) and at 8 years (n = 56) (Su et al., 2015). 
Children were classified into “high” and “low” exposure groups 
depending on the PCDD/PCDFs + PCBs levels found in placentas. IGFBP- 
3 was significantly higher in female newborns with high exposure levels 
compared with females of the low exposure group (Wang et al., 2005). 
Furthermore, IGF-1 and IGFBP-3 levels positively associated with 
placental weight and birth weight. On the other hand, IGFBP-3 was 
significantly lower in 8-year old girls prenatally exposed to high levels of 
PCBs (Su et al., 2015). In the high exposure group, 5-year old children, 
IGF-1 levels were higher compared to the low-exposed group, with a 
more pronounced effect in males (Su et al., 2010). In this cohort, 
exposure to PCDD/PCDFs and PCBs was associated with adverse effects 
on anthropometric parameters (birth length, height and weight) and 
thyroid hormones. These studies are of considerable interest since 
children with reported prenatal exposure were followed up at different 
time points. However, the participant numbers are rather small (<100 
individuals), with effects reported only at a specific age, which is likely 
to contribute to inconsistencies in reported outcomes. Results from Su 
and colleagues (Su et al., 2010) were partially confirmed in another 
longitudinal cohort study, in which exposure to dioxin-like compounds 
(PCBs and PCDD/Fs, measured in the breast milk of 418 women), was 
associated with increased IGF-1 levels in the blood of infants aged 3 
months, along with accelerated height and weight gain (Wohlfahrt-Veje 
et al., 2014). On the other hand, in a cohort of 456 adults, total circu-
lating dioxin-like PCBs (DL-PCBs), PCB-156 and PCB-167 negatively 
associated with plasma IGF-1 (Luzardo et al., 2012). However, in this 
study only DL-PCBs were considered, whereas the previous studies 
investigated a more complex mixture, including PCDD/Fs. Effects of 
complex chemical mixtures should be taken into account since they are 
likely to complicate comparison of findings. 
Overall, results of these studies suggest that exposure to dioxins and 
dioxin-like compounds is associated to increased IGF-1 in children and 
decreased IGF-1 in adults. It is possible that dysregulation of the IGF 
system may occur in different ways depending on timing of exposure 
(prenatal/children vs. adult). As evidence is still limited, these associa-
tions need to be confirmed by new studies, in order to clarify the effects 
of age, sex and chemical mixture evaluated. 
Table 1 
Summary of ED effects on the IGF axis in vitro.  
Chemical IGF 
axis 
Effect Cell line Dose 
(concentration) 
References 
TCDD IGF-1 = Human hepatocarcinona (HepG2) and cultured 
human hepatocytes 
25 nM (Marchand, 2004) 
IGF-2 ↓ Breast cancer (MCF-7) 10 nM (Salisbury et al., 2013) 
↑ Rat hepatoma (BRL-3A) 10 nM (Wang et al., 2011) 
= Human hepatocarcinona (HepG2) and cultured 
human hepatocytes 
25 nM (Marchand, 2004) 
IGF-1R  ↓ Breast cancer (MCF-7) 0.01–10 nM (Liu et al., 1992) 
↑  Mammary epithelium (MCF-10A) 
Breast cancer (MCF-7) 
30 nM 
0.1–10 nM 
(Tannheimer et al., 1998) 
(Tanaka et al., 2007) 
= Human hepatocarcinona (HepG2) and cultured 
human hepatocytes 
25 nM (Marchand, 2004) 
IGFBP- 
1 
↑ Human hepatocarcinoma (HepG2) 10 nM 
25 nM 
0.1–100 nM 
(Adachi et al., 2004;Marchand, 2004;Murray and Perdew, 2007) 
IGFBP- 
2 
= Human hepatocarcinona (HepG2) and cultured 
human hepatocytes 
25 nM (Marchand, 2004) 
IGFBP- 
3 
↑ Breast cancer (MCF-7) 5 nM (Widerak et al., 2006) 
IGFBP- 
4 
↑ Rat hepatoma (5L) (possible genetic alteration of 
cell line) 
0.001–1 nM (Brandner et al., 2013) 
= Human hepatocarcinona (HepG2) and cultured 
human hepatocytes 
25 nM (Marchand, 2004) 
IGFBP- 
5 
↓ Breast cancer (MCF-7) and human endometrial 
carcinoma (RL95-2) 
0.1–10 nM (Tanaka et al., 2007) 
IGFBP- 
6 
↑ Murine thymoma (EL-6) 10 nM (Park et al., 2001) 
B[a]P IGF-1 ↓ Human placenta trophoblast (HTR-8) 1–5 μM (Fadiel et al., 2013) 
IGF1-R ↓ Vascular smooth muscle cell 10 μM (Karyala et al., 2004) 
Mouse metanephric culture 3 μM (Nanez et al., 2011) 
↑ Mammary epithelium (MCF-10A) 0.03–3 μM (Tannheimer et al., 1998) 
IGFBP- 
7 
↓ Vascular smooth muscle cell 10 μM (Karyala et al., 2004) 
PFOS IGFBP- 
1 
↓ Human decidual stromal cells 0.0001–1 μM (Yang et al., 2016) 
BPA IGF-1 ↓  hESC-derived embryonic bodies 1 μM (B. Huang et al., 2017) 
Human ovarian granulosa-like tumor 40–100 μM (Kwintkiewicz et al., 2010) 
↑ Human uterine leiomyoma 1–20 μM (Shen et al., 2014) 
IGF-1R ↑ Human ovarian adenocarcinoma (BG-1) 10 μM 
10 μM 
(Hwang et al., 2013;Kang et al., 2013) 
IGFBP- 
1 
↑↓ Human endometrial stromal cells 5–100 μM 
0.1 nM-10 μM 
1 pM − 1 μM 
10 pM- 10 μM 
(Aghajanova and Giudice, 2011;Forte et al., 2016;Mannelli et al., 
2015;Xiong et al., 2020) 
IGFBP- 
4 
↑ Ovarian adenocarcinoma 10 μM (Hwang et al., 2011)  
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Table 2 
Summary of ED effects on the IGF axis in vivo.  
Chemical IGF Effect Tissue Exposure (model) Dose (concentration) References 
TCDD IGF-1 ↓ Liver Prenatal and lactational (rat, 
female) 
1 μg/kg bw (GD15) (Chaffin et al., 1996) 
Circulating Adult (rat) 0.0125–3.2 μg/kg bw /day +
maintenance (2–128 days) 
100 μg/kg 
(Croutch et al., 2005;Lindén et al., 
2014) 
IGF-2 ↓ Liver (F1 and F3) Prenatal, transgenerational (rat, 
only males) 
0.2/0.8 μg/kg bw/day (GD 8–14) (Ma et al., 2015) 
Placenta (F1 and F3) Prenatal, transgenerational 
(mice, only males) 
10 μg/kg bw (GD15) (Ding et al., 2018) 
Ovary Prenatal (rat, only female) 0.1/0.5 μg/kg bw/day (GD 8–14) (Zhang et al., 2019b) 
Total embryo Prenatal (mouse) 10 nM (blastocyst culture medium) (Wu et al., 2004) 
↑ Liver Prenatal (rat) 10 μg/kg bw (GD10) (Wang et al., 2011) 
= Kidney, skeleton, skeletal 
muscle 
Prenatal (rat) 10 μg/kg bw (GD10) (Wang et al., 2011) 
IGF-2R ↓ Muscle, liver Prenatal (mice, males) 0.002/0.01 μg/kg bw /day (GD9-19) (Somm et al., 2013) 
↑ Sperm Prenatal (mice, males) 0.002/0.01 μg/kg bw /day (GD9-19) (Somm et al., 2013) 
IGFBP- 
1 
↑ Liver Adult (mice) 40 μg/kg bw (4 days) (Minami et al., 2008) 
Kidney Lactational (mice) 20 μg/kg bw (PND1) (Yoshioka et al., 2014) 
IGFBP- 
5 
↓ Liver, calvaria (female) Prenatal (mouse) 5 μg/kg bw (GD12) (Tanaka et al., 2007) 
↑ Brain Prenatal (mouse) 5 μg/kg bw (GD12) (Tanaka et al., 2007) 
IGFBP- 
6 
↑ Calvaria Prenatal (rat) 5/10/15 μg/kg bw (GD10) (Guo et al., 2007) 
Thymus, bone marrow Adult (mice) 30 μg/kg bw (3 days) (Park et al., 2001) 
PCBs IGF-1 ↓ Circulating Early-weaned (rat), Prenatal 
(rat), 
Adult (rat) 
PCB-95: 32 mg/kg bw (PND15-16) 
PCB-126: 20/40 μg/kg bw (GD1-20) 
PCB-126: 1.6 mg/kg bw 
(Ahmed, 2013;Ahmed et al., 2018; 
Ronis et al., 2020) 
IGF-2 ↓ Circulating Prenatal (rat) PCB-126: 20/40 μg/kg bw (GD1-20) (Ahmed et al., 2018) 
IGFBP- 
3 
↑ Duodenum Adult (rat) PCB-126: 0.1–1 μg/kg bw (13 weeks) (Lee et al., 2000) 
B[a]P IGFBP- 
6 
↑ Liver Adult (mice) 100 mg/kg bw (Bartosiewicz et al., 2001) 
= Kidney Adult (mice) 100 mg/kg bw (Bartosiewicz et al., 2001) 
PBDE IGF-1 ↑ Circulating (only males) Perinatal (rat) BDE-47:2/200 μg/kg bw (GD15- 
PND20 every 5 days)  
(Suvorov et al., 2009) 
Uterus Prenatal (rat) PBDE-99: 1/10 mg/kg bw /day 
(GD10-18) 
(Ceccatelli et al., 2006) 
Phthalates IGF-1 ↑ Testes Prenatal (rat) DEHP: 10/100/750 mg/kg bw /day 
(GD2-20) 
(Lin et al., 2008) 
Wolffian duct Prenatal (rat) DBP: 500 mg/kg bw /day (GD12-21) (Bowman et al., 2005) 
Circulating Prepubertal (rat) DEHP: 0.2/1/5 mg/kg bw /day (4 
weeks) 
(Shao et al., 2019) 
Hypothalamus Prepubertal (rat) DEHP: 0.2/1/5 mg/kg bw /day (4 
weeks) 
(Shao et al., 2019) 
↑↓ Hypothalamus 
(depending on dose) 
Prepubertal (rat) DEHP: 250/500/1000 mg/kg bw 
/day (4 weeks) 
(Liu et al., 2018) 
IGF-2 ↑ Wolffian duct Prenatal (rat) DBP: 500 mg/kg bw /day (GD12-21) (Bowman et al., 2005) 
IGF-1R ↑ Wolffian duct Prenatal (rat) DBP: 500 mg/kg bw /day (GD12-21) (Bowman et al., 2005) 
Hypothalamus Prepubertal (rat) DEHP: 0.2/1/5 mg/kg bw /day (4 
weeks) 
(Shao et al., 2019) 
= Testes Prenatal (rat) DEHP: 10/100/750 mg/kg bw /day 
(GD2-20) 
(Lin et al., 2008) 
IGFBP- 
1 
↑ Liver Adult (mice) DEHP: 1100 mg/kg bw (Bartosiewicz et al., 2001) 
= Kidney Adult (mice) DEHP: 1100 mg/kg bw (Bartosiewicz et al., 2001) 
IGFBP- 
5 
↑ Wolffian duct Prenatal (rat) DBP: 500 mg/kg bw /day (GD12-21) (Bowman et al., 2005) 
PFOS IGF-1 ↓ Liver, Testes Adult (mouse) PFOS: 1/5/10 mg/kg bw /day (21 
days) 
(Wan et al., 2011) 
IGF-1R ↓ Testes Adult (mouse) PFOS: 1/5/10 mg/kg bw /day (21 
days) 
(Wan et al., 2011) 
BPA IGF-1 ↓ Uterus Perinatal (rat, female) 0.5/50 μg/kg bw /day (GD9-PND21) (Vigezzi et al., 2015) 
↑ Placentome (trend) Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
Circulating Pubertal (rat) 3 mg/kg bw /day (5 weeks) (Herath et al., 2004) 
Liver Neonatal (rat, female) 6.25/62.5 mg/kg bw /day (PND1-10) (Ramirez et al., 2012) 
Mammary gland Adult (mouse) 0.5/500 μg/kg bw /day (PND56-112) (Jenkins et al., 2011) 
= Circulating Neonatal (rat, female) 6.25/62.5 mg/kg bw /day (PND1-10) (Ramirez et al., 2012) 
Ovaries Adult (rat, female) Diet supplemented 0.1/1% (Toda et al., 2002) 
↑ Placentome (trend) Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
= Ovaries Adult (rat, female) Diet supplemented 0.1/1% (Toda et al., 2002) 
IGF-1R ↓ Placentome Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
Uterus Perinatal (rat, female) 0.5/50 μg/kg bw /day (GD9-PND21) (Vigezzi et al., 2015) 
↑ Mammary gland Adult (mouse) 0.5/500 μg/kg bw /day (PND56-112) (Jenkins et al., 2011) 
= Ovaries Adult (rat, female) Diet supplemented 0.1/1% (Toda et al., 2002) 
IGF-2R ↑ Placentome Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
IGFBP- 
1 
↑ Placentome Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
(continued on next page) 
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2.2. Polycyclic aromatic hydrocarbons (PAHs) 
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environ-
mental contaminants with known carcinogenic, teratogenic and endo-
crine disrupting action (Boström et al., 2002; Idowu et al., 2019). They 
are persistent and highly lipophilic, therefore can easily accumulate in 
living organisms. PAHs are released as a result of incomplete combus-
tion of organic matter, for example in industrial emissions and tobacco 
smoke. PAHs are known ligands of the aryl hydrocarbon receptor (AhR) 
and benzo[a]pyrene (B[a]P) is normally used as the reference com-
pound in toxicological studies. Evidence linking PAH treatment/expo-
sure to changes in the IGF system is summarised in Table 1 and 2. 
The interaction between B[a]P and the IGF pathway was first eval-
uated in a human mammary epithelial cell line. It was found that, under 
insulin-deficient conditions, B[a]P activated the IGF-1 pathway, 
mimicking signalling through IGF-1R (Tannheimer et al., 1998). In these 
experiments, the absence of insulin might have played a significant role 
and, therefore, the results should be interpreted with caution. Subse-
quent studies supported a negative effect of B[a]P on IGF signalling. For 
example, in vascular smooth muscle cells, B[a]P treatment decreased 
IGF-1R and IGFBP-7 (Karyala et al., 2004). IGF-1R was also found to be 
decreased upon B[a]P in a mouse metanephric culture (Nanez et al., 
2011). In a human placental trophoblast cell line, B[a]P significantly 
reduced IGF-1 expression in a dose-dependent manner (Fadiel et al., 
2013). Furthermore, as B[a]P treatment caused mutations in IGF-1, the 
authors hypothesised that the predicted altered structure would 
decrease affinity of the protein for the receptor (Fadiel et al., 2013). 
These findings are of particular interest since IGF-1 is known to be 
involved in placenta growth and function (Forbes and Westwood, 2008). 
Unfortunately, only one relevant study has been reported in animals. 
Using DNA microarray, it was reported that mice exposed to B[a]P had 
an increased level of IGFBP-6 in the liver, whereas no change was re-
ported in the kidney (Bartosiewicz et al., 2001). The principal function 
of IGFBP-6 is inhibiting IGF-2 actions, but also IGF-independent actions 
have been described (Bach, 2015). Overall, these studies would indicate 
that B[a]P exposure negatively impacts the IGF system, however evi-
dence is still limited. In particular, new studies are required to confirm 
the implications of the dysregulation of the IGF system in the placenta. 
The association between PAHs exposure and the IGF system has been 
investigated in a couple of epidemiological studies (Table 3). In a cohort 
of pregnant women/newborn pairs living near an electronic waste site in 
China, 16 PAHs were measured in cord blood and IGF-1 and IGFBP-3 
transcript quantified in placental tissue. Exposure to PAHs was associ-
ated with increased birthweight. A positive correlation of total 5-ring 
(Σ5-ring) PAHs with IGF-1 placental mRNA expression was found. On 
the other hand, total PAHs (Σ16PAHs) and total 4-ring (Σ4-ring) PAHs 
correlated with IGFBP-3 expression in the placenta (Xu et al., 2013). 
This is in contrast to results by Fadiel et al., who reported that B[a]P 
treatment reduced IGF-1 expression in a trophoblast cell line (Fadiel 
et al., 2013). However, given that the placenta is a very dynamic organ, 
differences exist between human placental trophoblast cells (HTR-8, 
which are immortalised human first trimester extravillous trophoblast 
cells), and placental tissue collected at term. Another element to be 
considered is the effect of the complex mixture of PAHs, which is likely 
to have different actions than from B[a]P exposure only. In a recent 
study on 238 children, a negative association was reported between 
exposure to atmospheric PM2.5-bound PAHs and IGF-1 plasma levels and 
child height (Zeng et al., 2020). Methodological differences, such as 
measurement of PAH levels in cord blood compared to the environment 
(atmospheric PAHs), or IGF-1 measured in the placenta compared with 
plasma, make findings from these two epidemiological studies difficult 
to compare. 
Taken together, the lack of animal models and the limited evidence 
provided by in vitro and epidemiological studies, definitive conclusions 
about the impact of PAHs on the IGF system are not possible. 
2.3. Polybrominated diphenyl ethers (PBDEs) 
Polybrominated diphenyl ethers (PBDEs) are organobromine com-
pounds widely used as flame retardants with known adverse health ef-
fects (Linares et al., 2015). 
Effects of exposure to these compounds have been evaluated in only 
a couple of animal studies (Table 2). In a rat model of perinatal exposure 
to BDE-47, male pups exhibited increased circulating IGF-1 levels after 
birth, whereas no effects were reported in females (Suvorov et al., 2009). 
Also, increased IGF-1 transcript was found in the uteri of rats prenatally 
exposed to PBDE-99 (Ceccatelli et al., 2006). 
In three epidemiological studies, the association between PBDE 
levels and IGF-1 and IGFBP-3 has been investigated in different cohorts 
and matrices (Shy et al., 2012; Xu et al., 2014, 2013). 
In the first study, 14 PBDEs were measured in breast milk from 149 
women and IGF-1 analysed in cord blood of their newborns. Total PBDEs 
(Σ14 PBDEs) did not correlate with IGF-1 and thyroid hormones cord 
blood levels. However, BDE-196 was positively associated with IGF-1, 
whereas BDE-85 showed a negative association (Shy et al., 2012). In 
the other two studies, only 8 PBDE congeners were evaluated (which did 
not include BDE-196 and BDE-85) (Xu et al., 2014, 2013). In children, 
circulating IGFBP-3 was positively associated with plasma levels of BDE- 
209 and negatively associated with BDE-47, but no significant associa-
tions were found with IGF-1. Total PBDEs were also negatively associ-
ated with free triiodothyronine (Xu et al., 2014). The third study 
reported that cord blood levels of BDE-154 and BDE-209 positively 
correlated with placental IGF-1 expression, while total PBDEs were 
associated with significantly higher placental IGFBP-3 transcript (Xu 
et al., 2013). These associations were more pronounced in females 
compared to males, but, surprisingly, PBDE exposure was not associated 
with changes in birthweight. The high variability of these studies makes 
the findings difficult to interpret. For example, BDE-209 was positively 
associated with IGFBP-3 in children (Xu et al., 2014), but not in new-
borns (Shy et al., 2012) or the placenta (Xu et al., 2013). On the other 
hand the positive association of BDE-209 with IGF-1 has been found only 
in the placenta (Xu et al., 2013). Reasons for discrepancies may arise 
because of different matrices used for the PBDE determination (breast 
milk vs. blood) and IGF measurements (blood vs. placenta). It is difficult 
to interpret the positive or negative associations with IGF elements 
depending on the specific PBDE evaluated, especially because evidence 
from animal studies is limited and no in vitro investigations have been 
reported. 
Table 2 (continued ) 
Chemical IGF Effect Tissue Exposure (model) Dose (concentration) References 
IGFBP- 
2 
↑ Placentome Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
IGFBP- 
3 
↑ Placentome Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
IGFBP- 
4 
↑ Placentome Gestational (sheep) 500 μg/kg bw /day (GD30-90) (Song et al., 2020) 
Bw: body weight 
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Table 3 
Summary of epidemiological evidence linking ED exposures to IGF expression levels and methylation.  
Chemical 
class 
Cohort Chemicals Tissue IGFs and IGFBPs Findings Study 
Dioxins and 
dioxin-like  
N = 118 
Pregnant women and 
newborns 
17 PCDD/PCDFs, 12 
PCBs  
Placenta IGF-1, IGFBP-3 
(cord blood) 
↑ IGFBP-3 in highly exposed group 
No effects on IGF-1  
(Wang et al., 
2005) 
N = 92 Pregnant 
women and children 
(2–5 years old) 
17 PCDD/PCDFs, 12 
PCBs  
Placenta IGF-1, IGFBP-3  ↑ IGF-1 in highly exposed group  (Su et al., 2010) 
N = 56 Pregnant 
women and children 
(8 years old) 
17 PCDD/PCDFs, 12 
PCBs  
Placenta IGF-1, IGFBP-3  ↓ IGFBP-3 in highly exposed group PCBs  (Su et al., 2015) 
N = 418 Women and 
children 
17 PCDD/PCDFs, 18 
PCBs 
Breast milk IGF-1  ↑ IGF-1 (Wohlfahrt- 
Veje et al., 
2014) 
N = 465 Adults 12 dioxin-like PCBs Blood IGF-1 ↓ IGF-1 (Luzardo et al., 
2012) 
N = 169 Pregnant 
women and newborns 
58 NDL-PCBs Blood IGF-2 methylation 
(cord blood) 
No association (Kobayashi 
et al., 2017b) 
N = 116 Pregnant 
women 
32 PCBs Placenta IGF-2 methylation 
(placenta) 
No association (Kappil et al., 
2016) 
N = 188 (Case- 
control, prenatal 
exposure during war) 
TCDD (historical 
information) 
– IGF-2 methylation 
(blood) 
No association (Giuliani et al., 
2018) 
PAHs N = 154 Newborns 16 PAHs Cord blood IGF-1, IGFBP-3 
(placenta) 
↑ IGF-1 with Σ5-ring PAHs 
↑ IGFBP-3 with Σ16PAHs and Σ4-ring PAHs 
(Xu et al., 2013) 
N = 238 Children PM2.5-bound PAHs Blood IGF-1, IGFBP-3 ↓ IGF-1 (Zeng et al., 
2020) 
N = 400 Women Not directly measured 
but PAHs exposure 
assumed 
Blood IGF-1, IGFBP-1  ↑ IGF-1 and IGFBP-1 in group living in 
ex-war area and with petrochemical 
industries 
(Tekle et al., 
2010) 




Urine IGF-1, IGFBP-3 ↓ IGF-1 with ΣDEHP metabolites and 
MCiOP 
↓ IGFBP-3 with ΣDEHP 
(Boas et al., 
2010) 
N = 216 Children 
(5–7 years) 
8 Phthalate metabolites Urine IGF-1, IGFBP-3 ↓IGF-1 with MMP and MBP 
↓ IGFBP-3 with MMP and MEP 
(Wu et al., 
2017) 
N = 219 Pregnant 
women and children 
(8–14 years) 
9 Phthalate metabolites Maternal and 
children urine 
IGF-1 ↑ IGF-1 and maternal ΣDEHP (pubertal 
girls) 
↓ IGF-1 and DBP, MBzP, and MCPP in boys 
↑ IGF-1 and ΣDEHP in girls 
(Watkins et al., 
2016) 
N = 79 < 18 years 
N = 279 Adults 
11 phthalates 
metabolites 
Urine IGF-1 ↓ IGF-1 and ΣDEHP in young 
↑IGF-1 and MEHP in adults 
(H. Huang 
et al., 2017) 
N = 88 Children 3 phthalates metabolites 
(estimated daily DEHP 
intake) 
Urine IGF-1, IGFBP-3 ↓ IGF-1 with estimated levels of daily 
DEHP intake 
No effect on IGFBP-3 
(Tsai et al., 
2016) 
N = 166 Children 9 phthalates metabolites Urine IGF-1, IGFBP-3 ↓ IGF-1 with MEP 
↓ IGFBP-3 with MEP and MMP 
(Huang et al., 
2020) 
N = 220 Pregnant 
women 
5 phthalates metabolites Urine IGF-2 methylation 
(placenta, maternal 
side) 
↓ IGF-2 methylation with MEHHP, MEOHP 
and ΣDEHP 
(Zhao et al., 
2016) 




Urine IGF-2 methylation 
(placenta) 
↓ IGF-2 methylation with MEP, MEOHP, 
ΣDEHP, Σphthalate, MEHP (females), 
MEOHP (females), MECCP (female) 
(LaRocca et al., 
2014) 
N = 109 Pregnant 
Women 
9 phthalates metabolites Urine IGF-2 methylation 
(cord blood) 
↓ IGF-2 methylation with MCPP, ΣDEHP, 
MEP (females) 
(Montrose 
et al., 2018) 
PFAS N = 2292 Children 
(6–9 years) 
PFOA, PFOS, PFNA, 
PFHxS 
Blood IGF-1 ↓IGF-1 with PFOS and PFNA (Lopez- 
Espinosa et al., 
2016) 
N = 177 Pregnant 
women and newborns 
PFOS, PFOA Blood IGF-2 methylation 
(cord blood) 
↓ IGF2 with PFOA (Kobayashi 
et al., 2017a) 
PBDE N = 149 Women 14 PBDEs Breast milk IGF-1 (cord blood) ↑IGF-1 with BDE-196 
↓IGF-1 with BDE-85 
(Shy et al., 
2012) 
N = 162 Children 
(4–6 years) 
8 PBDEs Blood IGF-1, IGFBP-3 ↑IGFBP-3 with BDE-209 
↓IGFBP-3 with BDE-47 
No effects on IGF-1 
(Xu et al., 2014) 
N = 154 Newborns 8 PBDEs Cord blood IGF-1, IGFBP-3 
(placenta) 
↑ IGF-1 with BDE-154, BDE-209 
↑ IGFBP-3 with total PBDEs 
(Xu et al., 2013) 
N = 116 Pregnant 
women 
10 PBDEs Placenta IGF-2 methylation 
(placenta) 
No association (Kappil et al., 
2016) 
BPA N = 219 Pregnant 
women and children 
(8–14 years) 
BPA Maternal and 
children urine 
IGF-1 No association (Watkins et al., 
2016) 
N = 56 Pregnant 
women 
BPA Urine IGF-2 methylation 
(cord blood) 
↓ IGF-2 methylation (females) (Montrose 
et al., 2018) 
Tissue refers to matrix used for chemical measurements. IGF-1 and IGFBPs were measured in blood unless stated otherwise. 
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2.4. Phthalates 
Phthalates are widely used as liquid plasticisers, therefore can be 
found in many products, including plastics and cosmetics (Wang et al., 
2019). Effects of exposure to these compounds have been evaluated in 
only a few animal studies (Table 2), which generally indicate an up- 
regulation of the IGF pathway. Impact of phthalate exposure on repro-
ductive development and puberty has been the main focus, considering 
that phthalates have an adverse effect on reproductive development and 
the IGF pathway plays a role in reproductive physiology. Rats prenatally 
exposed to bis(2-ethylhexyl) phthalate (DEHP) had higher testicular 
IGF-1 transcript level, whereas no effects were found on IGF-1R 
expression (Lin et al., 2008). IGF-1, IGF-2, IGF-1R and IGFBP-5 were 
up-regulated in the Wolffian ducts of rat fetuses prenatally exposed to 
DBP (Bowman et al., 2005). Furthermore, DEHP exposure increased 
circulating levels of IGF-1 and up-regulated IGF-1 and IGF-1R in the 
hypothalamus of prepubertal females (Liu et al., 2018; Shao et al., 
2019). The latter studies suggest that phthalate exposure might induce 
precocious puberty by affecting the hormone levels of GH and IGF-1 in 
the hypothalamus and serum. The sensitivity of adult animals exposed to 
DEHP has also been shown by the significant increase in IGFBP-1 in the 
liver but not in the kidney (Bartosiewicz et al., 2001). 
Associations between phthalate levels and IGFs and related proteins 
have been investigated mostly in children and an inverse association 
between urinary phthalate metabolites and circulating levels of IGF-1 
and IGFBP-3 consistently reported (Boas et al., 2010; H. Huang et al., 
2017; Huang et al., 2020; Tsai et al., 2016; Watkins et al., 2016; Wu 
et al., 2017). In the largest study (845 children) 12 phthalate metabolites 
were measured and ΣDEHP (sum of all DEHP metabolites) and MCioP 
were negatively correlated with both IGF-1 and IGFBP-3 (Boas et al., 
2010). Moreover, most phthalate metabolites were negatively associ-
ated with height, weight and serum levels of free and total triiodothy-
ronine (Boas et al., 2010). In another study, monomethyl phthalate 
(MMP) and mono-n-butyl phthalate (MBP) were inversely associated 
with IGF-1, whereas MMP and monoethyl phthalate (MEP) were 
inversely associated with IGFBP-3 (Wu et al., 2017). The negative as-
sociation between some phthalate metabolites (MEP and MMP) and IGF- 
1 and IGFBP-3 was also confirmed in a recent study (Huang et al., 2020). 
The finding of a negative association between the sum of urinary DEHP 
metabolites and IGF-1 has been recently confirmed in a cross-sectional 
study of 79 young individuals (<18 years of age) (H. Huang et al., 
2017). Following the major scandal occurring in Taiwan involving the 
illegal use of phthalates as clouding agents in food products, urinary 
concentrations of DEHP metabolites were quantified in 88 children and 
daily DEHP intake calculated. Estimated levels of DEHP intake was 
found to be negatively associated with IGF-1, height and weight without 
effect on IGFBP-3 (Tsai et al., 2016). In some studies, sex-specific asso-
ciations were found. For instance, in the only study evaluating the as-
sociation between prenatal phthalate exposure and IGF-1 levels in 
children, a positive association between total maternal DEHP metabo-
lites (measured in urine collected during the third trimester of preg-
nancy) and serum IGF-1 was found in pubertal girls only, although the 
size of this group was very small (n = 32) (Watkins et al., 2016). Simi-
larly, in prepubertal girls of the same cohort, total DEHP metabolites 
measured in their urine were positively associated with IGF-1 (Watkins 
et al., 2016). Moreover, phthalate metabolites were associated with 
metabolic biomarkers (leptin, glucose, c-peptide) in patterns that varied 
by sex, pubertal status, and exposure timing. These findings demonstrate 
that these variables need to be considered in such studies. In another 
study, monocarboxyisooctyl phthalate (MCiOP) was negatively associ-
ated with IGF-1 in boys and IGFBP-3 in girls (Boas et al., 2010). Among 
pubertal boys, a negative association between IGF-1 and several 
phthalate metabolites, including DBP, MBzP, and MCPP was reported 
(Watkins et al., 2016). Overall, it must be emphasised that IGF-1 levels 
rise steeply at puberty and are thought to play a role in the timing of 
puberty onset (Cole et al., 2015; Kanbur et al., 2005), representing a 
possible explanation for different findings in studies involving peri-
pubertal children. Indeed, in the only study with adults (n = 279), a 
positive association between IGF-1 and MEHP (H. Huang et al., 2017). 
We suggest puberty and/or age might contribute to difference in 
observed effects. 
In most of these epidemiological studies, thyroid hormones were also 
evaluated and positive or negative associations were found depending 
on the individual phthalate metabolite (Boas et al., 2010; H. Huang 
et al., 2017; Huang et al., 2020; Wu et al., 2017). 
2.5. Perfluoroalkyl substances (PFAS) 
Perfluorinated alkylated substances (PFAS) are man-made chemicals 
with extensive use in industry, for example in fire foams, paints and 
detergents (Sunderland et al., 2019). The evidence linking PFAS and IGF 
is very limited (Table 1 and Table 2). 
In human endometrial stromal cells, PFOS decreased IGFBP-1 tran-
script (Yang et al., 2016). PFOS exposure was associated with down- 
regulation of IGF-1 and IGF-1R transcript in mice testes, furthermore 
IGF-1 was decreased also in the liver (Wan et al., 2011). Association 
between IGFs and PFAS has been evaluated in only one epidemiological 
study. It was found that serum PFAS concentration (PFOS and PFNA) 
were associated with lower levels of IGF-1 and sex hormones in 2292 
children of 6–9 years of age (Lopez-Espinosa et al., 2016). This is 
currently the largest epidemiological study evaluating the effects of 
exposure to EDs on the IGF system. Although limited, in vitro and in vivo 
investigations support the conclusion of a negative effect of PFAS on the 
IGF system, suggesting that confirmatory studies are needed to confirm 
the findings. 
2.6. Bisphenol A 
Bisphenol A (BPA) is a plastic monomer used in the production of 
polycarbonate plastics, epoxy resins and in consumer products. It is 
possibly one of the most investigated endocrine disruptors, although 
many findings are controversial (Vandenberg et al., 2007). BPA expo-
sure reportedly affects several molecules of the IGF system in several cell 
models (Table 1). BPA decreased IGF-1 during human embryonic body 
differentiation (B. Huang et al., 2017). In human ovarian granulosa-like 
tumor cells, BPA reduced FSH-induced IGF-1 expression (Kwintkiewicz 
et al., 2010). On the other hand, BPA treatment of uterine leiomyoma 
cells led to an increased transcript expression and protein level of IGF-1 
(Shen et al., 2014). Induction of IGF1-R was also demonstrated in human 
ovarian carcinoma cell lines (Hwang et al., 2013; Kang et al., 2013). BPA 
treatment significantly induced IGFBP-1 secretion in endometrial stro-
mal cells (Aghajanova and Giudice, 2011), but the finding was not 
confirmed in subsequent studies (Forte et al., 2016; Mannelli et al., 
2015; Xiong et al., 2020). In ovarian carcinoma cells, BPA was able to 
significantly up-regulate IGFBP-4 transcript (Hwang et al., 2011). In 
these cell-based studies a great range of BPA dose levels have been used 
(from 1 pM to 100 μM), which could explain the high variability in the 
results reported. 
Dysregulation of IGF signalling upon BPA treatment has been 
demonstrated in several animal studies, particularly in prenatal expo-
sure scenarios (Table 2). BPA exposure effects on developmental pro-
gramming of the placenta has been investigated in a sheep model (Song 
et al., 2020). Placentomes were collected at 2 different time points, at 
gestational day 65 (GD65, early gestation) and at GD90 (mid gestation). 
IGF-2R, IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-4 transcripts were 
increased in the BPA-treated group, whereas IGF-1R was down- 
regulated. IGF-1 and IGF-2 levels tended to be up-regulated, without 
statistical significance. This represents one of the few studies in which a 
comprehensive characterisation of the IGF system was provided, 
although limited to one tissue. 
Female rats exposed to BPA during the neonatal period, showed an 
increased IGF-1 in the liver, with levels approaching those reported in 
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males, indicating a masculinization of the system. However, levels of the 
circulating protein was not affected (Ramirez et al., 2012). But male 
pubertal rats exposed daily to BPA showed increased circulating levels of 
IGF-1 (Herath et al., 2004). Time of exposure (postnatal vs. pubertal) 
and treatment (62.5 mg/kg body weight for 10 days vs 3 mg/kg body 
weight for 5 weeks) might explain difference in the findings. Further-
more, induction of IGF-1 and increased phosphorylation of IGF-1R was 
reported in mammary glands of adult mice chronically exposed to BPA 
(Jenkins et al., 2011) and of rats exposed during the early postnatal 
period (Lamartiniere et al., 2011). On the other hand, female rats 
exposed to BPA during the prenatal period and lactation showed 
decreased uterine expression levels of IGF-1 and IGF-1R transcript 
(Vigezzi et al., 2015). In contrast, BPA exposure did not affect IGF-1, 
IGF-2 and IGF-1R expression in ovaries of adult mice (Toda et al., 2002). 
The association between BPA and IGF-1 has been investigated in only 
one epidemiological study (Table 3). In a cohort of 250 children, 
exposure to BPA in utero was not associated with IGF-1 serum levels or 
other markers of metabolic homeostasis (Watkins et al., 2016). 
3. Epigenetics and potential mechanisms 
3.1. Methylation studies 
It is important to emphasise that IGF-2 is a paternally-expressed 
imprinted gene and its expression is epigenetically controlled by 
several differentially methylated regions (DMRs) (Willison, 1991). The 
methylation pattern is established early in development and it plays a 
role in regulating fetal growth and development (St-Pierre et al., 2012). 
Altered IGF-2 methylation is implicated in human growth disorders, like 
the Silver-Russel syndrome (Binder et al., 2008). On the other hand, the 
gene encoding for IGF-2R is maternally expressed (Latham et al., 1994). 
Increasing evidence supports the role of epigenetic changes induced by 
EDs as one of the mechanisms responsible for long-lasting and trans-
generational health effects (Alavian-Ghavanini and Rüegg, 2018). Thus, 
IGF-2 and IGF-2R represent two potential targets for epigenetic changes 
associated with EDs exposure. However, the findings related to this 
mechanism have been mixed. 
In male mice exposed prenatally to TCDD, significant changes in the 
methylation patterns in two of the major control regions of IGF-2 were 
reported in DNA from liver tissue, with internal control region (ICR) 
being hypermethylated whereas DMR2 was hypomethylated (Ma et al., 
2015). In another transgenerational study evaluating prenatal exposure 
to TCDD on males, hypomethylation of IGF-2 in sperm in F1 and F3 
generation was found (Ding et al., 2018). In females, TCDD did not alter 
the mean methylation rate of DMR2 and ICR, and hypermethylation was 
reported for some CpG sites only (Zhang et al., 2019b). In mice prena-
tally exposed to TCDD only during the preimplantation stage, an 
increased level of methylation of the IGF2/H19 imprint control region 
has been found (Wu et al., 2004). The effects of in utero exposure to 
TCDD on IGF-2R was investigated only in one study of male offspring. 
An increased level of methylation, at the DMR2, in both liver and muscle 
was associated to the exposure (Somm et al., 2013). Evidence related to 
other chemicals is very limited. Prenatal B[a]P exposure did not affect 
IGF-2 methylation in sperm (Zhang et al., 2019a). Prenatal exposure to 
BPA decreased methylation in fetal mouse germ cells (Zhang et al., 
2012). Also, IGF-2R hypomethylation after BPA treatment in mice oo-
cytes was confirmed also in a model of postnatal exposure (Chao et al., 
2012). Mixed effects on methylation have been reported, with differ-
ences in tissue and exposure timings will all contribute to the differences 
observed. 
Similarly, findings in humans have been controversial (Table 3). 
Prenatal exposure to non-dioxin like PCBs (as measured in maternal 
blood) was not associated with IGF-2 methylation levels in cord blood 
(Kobayashi et al., 2017b). Similarly, in a study evaluating the placenta, 
no association between IGF-2 methylation and PCBs and PBDEs levels 
was found (Kappil et al., 2016). In a case-control study evaluating the 
Vietnamese population exposed to TCDD during the Vietnam war, many 
CpGs sites in IGF-2 gene showed significant differences but findings 
were no longer significant when false discovery rate was applied (Giu-
liani et al., 2018). Prenatal exposure to PFOA was associated with a 
decrease in IGF-2 methylation in cord blood, whereas no effect was 
associated with PFOS in a cohort of 177 mother-children pairs 
(Kobayashi et al., 2017a). Several phthalate metabolites have been 
associated with decreased methylation of IGF-2 in the placenta and in 
cord blood (LaRocca et al., 2014; Montrose et al., 2018; Zhao et al., 
2016). Furthermore, maternal urine BPA (measured in the first 
trimester) was negatively associated with IGF-2 methylation in cord 
blood of female newborns only (Montrose et al., 2018). Overall, 
although evidence from animal models is still limited, epidemiological 
studies support the association between exposure to some EDs and IGF-2 
hypomethylation in cord blood. 
3.2. Potential mechanisms of ED action on IGF signalling 
The evidence presented here largely supports the hypothesis of cross- 
talk between the IGF system and AhR as one of the possible mechanisms 
responsible for growth and metabolic disruption associated with di-
oxins, dioxin-like compounds and PAHs. The effects of these chemicals 
are mediated by the AhR (Connor and Aylward, 2006). Upon activation 
by its ligand, AhR is translocated into the nucleus and forms a hetero-
dimer with the AhR receptor nuclear translocator. This heterodimer 
binds to specific responsive elements defined xenobiotic-responsive el-
ements (XREs), also known as dioxin-responsive elements, and subse-
quently induces the expression of down-stream genes. Several authors 
identified XRE sequences in the promoter region of IGFBP-1 (Adachi 
et al., 2004; Marchand, 2004; Murray and Perdew, 2007). The possible 
interaction between AhR and IGF signal transduction pathways has also 
been directly investigated, mainly through studies with functional 
inactivation of AhR. The regulation of IGFBP-1 transcription impacted 
by TCDD exposure in HepG2 cells was found to be AhR-dependent 
(Murray and Perdew, 2007). In a hepatocyte AhR knock-out mouse 
model, IGFBP-1 was significantly increased in the liver (Girer et al., 
2016). The finding was replicated in another study investigating hepatic 
mRNA expression profile in AhR-null mice. Again IGFBP-1 was identi-
fied among the top up-regulated genes (Minami et al., 2008). At the 
same time, TCDD treatment was able to induce IGFBP-1 in the liver only 
in wild-type mice and not in the AhR knockout model, supporting the 
hypothesis that IGFBP-1 induction by TCDD requires a functional AhR, 
in line with the other studies (Minami et al., 2008). Overall, these 
findings support the hypothesis of AhR acting as a suppressor of IGF 
pathway, mainly via up-regulation of IGFBP-1, which in turn would 
decrease IGFs bioavailability (Fig. 1). 
There are indications that other elements of IGF pathway might be 
also part of a regulatory loop with AhR, although less well supported by 
findings from studies. For instance, TCDD significantly inhibited IGF-2 
mediated proliferation in a breast cancer cell line, and this growth in-
hibition was dependent on the presence of a functional active AhR 
(Salisbury et al., 2013). A subsequent study confirmed that IGF-2 pro-
moted cell proliferation of breast cancer cells by inducing AhR (Tomblin 
and Salisbury, 2014). In vascular smooth cells, B[a]P treatment 
decreased IGF-1, IGF-1R, IGFBP-2 and IGFBP-7, but in cells with func-
tional inactivation of AhR, the expression levels of IGF-related genes 
increased (Karyala et al., 2004). B[a]P treatment in the embryonic 
kidney downregulated IGF-1R, but the effect was no longer present in 
case of a mutation in AhR allele (Nanez et al., 2011). In a study evalu-
ating AhR expression in breast tumour tissues of 439 patients, a positive 
correlation has been found between AhR and IGF-2R and IGF-1R, 
whereas no correlation was found with IGF-2 and IGFBP-5 (Vacher 
et al., 2018). Overall, these studies suggest that a functionally active 
AhR is required to regulate expression of IGFBP-1, which has been 
confirmed as a downstream target of AhR signalling. Other studies 
suggest that cross-talk between AhR and other elements of the IGF 
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system occurs, although the molecular mechanisms currently remain 
unknown. 
IGF-AhR crosstalk is likely not the only mechanism involved in 
mediating the effects of exposure to endocrine disruptors. For example, 
it has been suggested that the cross-talk between AhR and the estrogen 
receptor (ER) or the estrogen receptor alone should be considered as a 
potential mechanisms of action. Indeed, the interactions between es-
trogen signalling and the IGF system are widely described and the 
production of several IGFBPs are estrogen-responsive (Clemmons, 2018; 
Kahlert et al., 2000). PBDEs are mostly known for their thyroid- 
disrupting properties, however they can interact with both the AhR 
and ER (Meerts et al., 2001). Phthalates and BPA exert their endocrine- 
disrupting actions via dysregulation of estrogen signalling, among 
others (Acconcia et al., 2015; Benjamin et al., 2017; Rochester, 2013). 
Both XRE and estrogen responsive elements motifs were found in 
IGFBP-5 and IGF-1R genes in a study of the effects of developmental 
exposure to TCDD in the fetal mouse (Tanaka et al., 2007). Prenatal 
exposure to TCDD up-regulated IGFBP-6 in rat fetal calvaria and an ER 
genomic binding site was found in the promoter region of the gene, 
whereas no XREs were found (Guo et al., 2007). Furthermore, TCDD was 
able to induce IGFBP-6 in EL-4 cells deficient of the AhR, therefore 
suggesting that TCDD-IGFBP6 crosstalk was AhR-independent (Park 
et al., 2003). 
In order to investigate whether prenatal exposure to PBDE-99 
interfered with estrogen responsiveness later in life, female rats were 
ovariectomised and then challenged with estradiol (E2). It was found 
that PBDE-99 exposure dose-dependently reduced the magnitude of IGF- 
1 mRNA induction by E2 in ovariectomized animals (Ceccatelli et al., 
2006). Similarly, BPA induces proliferation of ovarian cancer cells via 
cross-talk between ER and IGF1-R signalling pathways (Hwang et al., 
2013; Kang et al., 2013). In another study, Toda et al. showed that BPA 
exposure in did not affect IGF-1, IGF-2 and IGF-1R in wildtype mice but 
that IGF-1 expression was elevated and IGF-1R downregulated in ovaries 
of exposed mice lacking aromatase activity (ArKO) and therefore having 
little endogenous estrogens (Toda et al., 2002). E2 administration led to 
recovery of the expression of these genes, confirming that transcription 
of IGF-1 and its receptor was regulated by E2 (Toda et al., 2002). 
Furthermore, BPA caused IGF-2R hypomethylation in mouse oocytes but 
the methylation pattern was recovered when an ER inhibitor 
(ICI182780) was added (Chao et al., 2012). 
Other possibilities have been suggested. For example, TCDD induced 
IGF-2 transcriptional activation via the CCAAT/enhancer binding pro-
tein β (C/EBP β) and a putative C/EBPβ responsive element was iden-
tified on the IGF-2 promoter, whereas no XRE was found (Wang et al., 
2011). Also, PPARγ might be involved in cross-talk with the IGF system, 
because it regulates signalling pathways downstream of IGF receptors 
and is involved in insulin sensitivity (Belfiore et al., 2009). Indeed, in 
granulosa cells, BPA reduced FSH-induced IGF-1 expression and signif-
icantly upregulated PPARγ (Kwintkiewicz et al., 2010). The central role 
played by PPARγ was confirmed as overexpression of PPARγ mimicked 
the effects of BPA on IGF-1 (Kwintkiewicz et al., 2010). 
Considering the available evidence, dysregulation of the IGF system 
by endocrine disruptors appears to be mainly mediated by AhR and/or 
ER. At the moment, only IGFBP-1 has been confirmed as a direct 
downstream gene in AhR signalling. However, AhR itself interacts with 
the ER, with AhR able to modulate estrogen signalling depending on the 
cellular context and type of exposure (Ohtake et al., 2011, 2003). 
Therefore, a more complex regulation, involving several signalling 
pathways, could be involved with the IGF system. New functional 
inactivation studies providing a comprehensive characterisation of IGF 
system in multiple organs are needed to fully elucidate impact of AhR/ 
ER (and vice versa). It should also be taken into account that cross-talk 
might be tissue-specific, therefore regulation mechanisms should be 
evaluated also locally. 
4. Discussion 
IGFs play a major role in growth and metabolism, thus it is important 
to consider the adverse impacts of IGF-disruption and its possible im-
plications for human health. The evidence summarised in this review 
supports the hypothesis that the IGF system should be considered a 
major target for EDs. Although the direction of specific effects are not 
always consistent, animal models have revealed the adverse conse-
quences of prenatal exposure to EDs on the IGF system, while many in 
vitro experiments provided mechanistic insight. Overall, it should be 
noted that studies presented in this review were highly heterogeneous, 
in terms of experimental models, dose levels and types/routes of expo-
sure. These aspects render the direct comparison of outcomes difficult 
and also hamper the translation of the findings of these studies to 
humans. Also, evidence provided in epidemiological studies is also 
somewhat inconclusive, with positive or negative association between 
ED exposure and IGF elements not being consistently reported, the ef-
fects, or lack thereof, often depending on specific chemicals and with 
effects found in one cohort only. 
Cell-based studies are rather limited in terms of the number of 
compounds tested and cell lines used. Some chemical classes have not 
yet been investigated in vitro (phthalates, PBDE), while for others only a 
few studies have been performed (B[a]P, PFOS). Perhaps predictably, 
BPA and TCDD have received more attention. A wide variety of cell lines 
have been used, and this is justified by the widespread actions of IGF 
system, which acts virtually in all cell types. However, in most cases only 
one study has been performed for each cell line. Due to this clear limi-
tation, findings need to be interpreted with caution. Moreover, in the 
few cases in which the same cell line was used, findings have not been 
consistently confirmed (see effects of BPA on IGFBP-1 in endometrial 
stromal cells). Possibly the only exception is the up-regulation of IGFBP- 
1 induced by TCDD in a hepatocarcinoma cancer cell line, which has 
been reported by multiple authors. It is clear that more in vitro studies 
are required to ensure reproducibility and establish clear dose response 
parameters. 
Another limitation of the published in vitro and animal studies is that 
few of them comprehensively characterised the IGF system, with most 
assessing only a limited number of IGF system elements. The IGF system 
is a complex signalling pathway, in which the interactions between IGFs, 
their receptors and binding proteins are responsible for downstream 
effects. Therefore, interpretation of findings based on observations 
related to a small section of the pathway could be misleading. More 
effort should be made in designing toxicological studies able to provide a 
more complete characterisation of the system. A major issue is related to 
great variability in study design between the publications. Although 
regulation of the IGF system is similar between mice and rats (Ohlsson 
et al., 2009), differences in timing of exposure and dose levels used make 
the findings of these studies difficult to compare. Moreover, tissue- 
specific effects should be taken into account. Besides the endocrine 
function, the autocrine and paracrine actions are also described for IGFs, 
which might indicate that the system is likely differentially regulated 
depending on specific cell type/organ. 
A large body of literature supports the negative impact of dioxins, 
dioxin-like compounds and PAHs on IGFs. Furthermore, the associated 
increased levels of IGFBPs (particularly IGFBP-1, mainly produced in the 
liver) would further reduce IGF bioavailability in a “double whammy” 
effect. Over-expression of IGFBP-1 is associated with growth retarda-
tion, impaired fertility and altered glucose homeostasis (Schneider et al., 
2000). In humans, high circulating IGFBP-1 levels have been linked with 
low birthweight (Tisi et al., 2005; Vatten et al., 2002; Wang et al., 1991). 
Therefore, these effects are likely to have significant health implications. 
While in vitro studies have provided mechanistic understanding, sup-
porting the role of AhR in IGF-disruption, epidemiological studies have 
yielded mixed results. 
In the case of PBDEs, phthalates and PFAS, the evidence is still 
limited, with only a few studies in animal models. Based on this limited 
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evidence, it appears that PBDE exposure stimulates IGF signalling, 
whereas, for PFAS, a negative association with IGFs has been more 
commonly reported. Perhaps, the highest level of disagreement between 
in vivo studies and epidemiology is for phthalate metabolites, for which 
induction of IGF-1 and IGFBP-1 has been reported in vivo. On the other 
hand, in most of the epidemiological studies, a negative association 
between IGF-1 and phthalate metabolites was found. Furthermore, the 
negative association between maternal phthalate metabolites and IGF-2 
methylation in newborns has also been consistently reported, strongly 
supporting the negative impact of this exposure during prenatal life. 
While BPA has been more extensively investigated, somewhat mixed 
findings have been reported. Furthermore, the only epidemiological 
study assessing BPA in conjunction with the IGF system did not find any 
association with IGF-1. 
Both in vitro and in vivo studies frequently report gene expression 
and protein changes in IGFBPs, whereas IGFs and their receptors were 
not affected. While the major function of IGFBPs is to regulate IGF 
bioavailability IGF-independent actions have also been reported 
(Clemmons, 2018). However, given, a high degree of functional 
redundancy and/or genetic compensatory mechanisms suggested by the 
lack of substantial phenotypes in IGFBP knockout models (Bach, 2018a; 
Murphy, 1998), it is difficult to predict the implications of increased 
levels of a subset of binding proteins in specific tissues. Despite over-
lapping functions, specific roles have recently been described for each 
IGFBP, depending on cell type and condition (Bach, 2018b). For 
instance, IGFBP-1 is specifically involved in liver regeneration and in 
responding to catabolic condition and its levels are negatively associated 
with biomarkers of cardiovascular disease (Bach, 2018a; Bae et al., 
2013; Haywood et al., 2019). 
Since 80–90% of IGF-1 is bound to IGFBP-3 (Jones and Clemmons, 
1995) epidemiological studies focus mostly on IGFBP-3. Decreased 
IGFBP-3 has been more consistently associated with phthalate exposure, 
whereas for the other ED classes only mixed findings have been re-
ported. Given the current evidence, it is therefore impossible to derive 
definitive conclusions and difficult to predict the clinical implication of 
IGFBP-3 dysregulation. It should also be highlighted that some authors 
considered IGFBP-3 as a confounding variable, rather than an outcome 
(Luzardo et al., 2012), whereas others quantified IGF-1 only (Lope-
z-Espinosa et al., 2016; Shy et al., 2012; Watkins et al., 2016; 
Wohlfahrt-Veje et al., 2014). However, as IGFBP-3 is the main serum 
carrier of IGF-1 and altered levels have now been associated with several 
diseases, its evaluation is of utmost importance. Furthermore, it is now 
clear that the other IGFBPs are also involved in many pathological 
processes, such as metabolic disease and cancer (Bach, 2018a; Baxter, 
2014). Therefore, the potential contributions of exposure to EDCs on 
IGFBP dysregulation represents a considerable gap in our knowledge, 
given that human epidemiological data are lacking. 
Overall, the evidence presented in this review is characterised by 
high degree of variability. One of the possible explanations is related to 
the complexity of the IGF system, which acts in an endocrine, paracrine 
and autocrine manner and is able to respond to a wide set of regulatory 
mechanisms, which differ based on developmental stage and sex. 
Transcription and subsequent action of IGF are partially GH-dependent, 
but their levels in blood are influenced by other hormones (estrogens, 
thyroid hormones and glucocorticoids), the immune system and also by 
nutritional status (Blum et al., 1993; Juul, 2003; Ranke and Wit, 2018). 
Furthermore, it is critically important that IGF-1 levels fluctuate across 
lifespan, peaking around puberty and then decreasing with age during 
adulthood (Juul, 2003). This factor might explain the sometimes 
different direction of findings in epidemiological studies, as well as 
differences depending on life stage of experimental models used. Sex is 
also an important variable to consider. Sex-stratified analyses of epide-
miological studies reported that effects were more pronounced in fe-
males (LaRocca et al., 2014; Montrose et al., 2018; Wang et al., 2005; 
Watkins et al., 2016; Xu et al., 2013). Unfortunately, in most of the 
animal studies sex was not considered or studies were performed in one 
sex only. GH secretion pattern depends on sex, and this in turn differ-
entially regulate sexually dimorphic liver functions, in rodent models 
(Adams et al., 2015; Ohlsson et al., 2009). For instance, liver-specific 
inactivation of IGF-1 feminizes GH-regulated liver functions (Walle-
nius et al., 2001). Finally, in humans there are indications of sexually 
dimorphic regulation of GH secretion and of interactions between sex 
steroids and IGF-1 in regulation of GH secretion (Ohlsson et al., 2009). 
An additional important point is that different classes of EDs might 
interfere with the IGF system in different ways. Therefore, the effects of 
complex mixture must be taken into account. 
Particular concerns arise from the observed effects associated with 
prenatal exposure to EDs, which has been reported in animal studies. 
The hypothesis that epigenetic modifications of the pathway following 
exposure to EDs has also been confirmed by animal models, while evi-
dence from human studies remains limited. In many human studies, a 
negative association between EDs (particularly phthalate metabolites) 
and IGF levels or methylation states have been found. The adverse 
impact of IGF disruption occurring during these critical windows of 
susceptibility is therefore probably an important mechanism in endo-
crine disruption of human development. However, it should be high-
lighted that most of the epidemiological studies are based on ED 
quantification in the maternal compartment (e.g. urine or blood), which 
does not necessarily reflect the actual human fetal exposure. 
4.1. Conclusions 
The IGF system plays a fundamental role in both growth and meta-
bolism. Although many studies have shown that EDs are able to disrupt 
IGF signalling, findings have been mixed, especially in human studies. It 
is evident, therefore, that research is still needed to fill research gaps and 
increase reproducibility of outcomes, or lack thereof. Additional animal 
studies are required in order to expand our knowledge about Eds that 
can disrupt the IGF system, in terms of system-wide changes and 
investigating the effects of complex mixtures. Furthermore, better 
designed epidemiological studies are needed to clarify the impacts on 
human health. Larger studies with simultaneous determination of more 
classes of EDs would be advantageous. In addition, given the importance 
of IGF signalling in regulating development, future areas of investigation 
should focus more sharply on effects of prenatal exposure to EDs, 
especially in the human. 
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Irigoyen, F., Vermeulen, R., Legler, J., Schoeters, G., 2018. Prenatal exposure to 
endocrine disrupting chemicals and risk of being born small for gestational age: 
Pooled analysis of seven European birth cohorts. Environ. Int. 115, 267–278. 
https://doi.org/10.1016/j.envint.2018.03.017. 
Guo, L., Zhao, Y., Zhao, Y.-Y., Sun, Z.-J., Liu, H., Zhang, S.-L., 2007. Toxic Effects of 
TCDD on Osteogenesis through Altering IGFBP-6 Gene Expression in Osteoblasts. 
Biol. Pharm. Bull. 30, 2018–2026. https://doi.org/10.1248/bpb.30.2018. 
Han, V.K., Bassett, N., Walton, J., Challis, J.R., 1996. The expression of insulin-like 
growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta 
and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. 
J. Clin. Endocrinol. Metab. 81, 2680–2693. https://doi.org/10.1210/ 
jcem.81.7.8675597. 
Haywood, N.J., Slater, T.A., Matthews, C.J., Wheatcroft, S.B., 2019. The insulin like 
growth factor and binding protein family: Novel therapeutic targets in obesity & 
diabetes. Mol. Metab. 19, 86–96. https://doi.org/10.1016/j.molmet.2018.10.008. 
Heindel, J.J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M.A., 
Nadal, A., Palanza, P., Panzica, G., Sargis, R., Vandenberg, L.N., vom Saal, F., 2017. 
Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol. 68, 
3–33. https://doi.org/10.1016/j.reprotox.2016.10.001. 
Heindel, J.J., Newbold, R., Schug, T.T., 2015. Endocrine disruptors and obesity. Nat. 
Rev. Endocrinol. 11, 653–661. https://doi.org/10.1038/nrendo.2015.163. 
Herath, C.B., Jin, W., Watanabe, G., Arai, K., Suzuki, A.K., Taya, K., 2004. Adverse effects 
of environmental toxicants, octylphenol and bisphenol A, on male reproductive 
functions in pubertal rats. Endocrine 25, 163–172. https://doi.org/10.1385/ENDO: 
25:2:163. 
Hewitt, S.C., Li, Y., Li, L., Korach, K.S., 2010. Estrogen-mediated regulation of Igf1 
transcription and uterine growth involves direct binding of estrogen receptor α to 
estrogen-responsive elements. J. Biol. Chem. 285, 2676–2685. https://doi.org/ 
10.1074/jbc.M109.043471. 
Hill, D.J., 1990. Relative abundance and molecular size of immunoreactive insulin-like 
growth factors I and II in human fetal tissues. Early Hum. Dev. 21, 49–58. https:// 
doi.org/10.1016/0378-3782(90)90110-5. 
Huang, B., Ning, S., Zhang, Q., Chen, A., Jiang, C., Cui, Y., Hu, J., Li, H., Fan, G., Qin, L., 
Liu, J., 2017. Bisphenol A Represses Dopaminergic Neuron Differentiation from 
Human Embryonic Stem Cells through Downregulating the Expression of Insulin-like 
Growth Factor 1. Mol. Neurobiol. 54, 3798–3812. https://doi.org/10.1007/s12035- 
016-9898-y. 
Huang, H., Pan, W.H., Chang, J.W., Chiang, H.C., Guo, Y.L., Jaakkola, J.J.K., Huang, P. 
C., 2017. Does exposure to phthalates influence thyroid function and growth 
hormone homeostasis? The Taiwan Environmental Survey for Toxicants (TEST) 
2013. Environ. Res. 153, 63–72. https://doi.org/10.1016/j.envres.2016.11.014. 
Huang, P.C., Chang, W.H., Wu, M.T., Chen, M.L., Wang, I.J., Shih, S.F., Hsiung, C.A., 
Liao, K.W., 2020. Characterization of phthalate exposure in relation to serum thyroid 
and growth hormones, and estimated daily intake levels in children exposed to 
phthalate-tainted products: A longitudinal cohort study. Environ. Pollut. 264 
https://doi.org/10.1016/j.envpol.2020.114648. 
Hwang, K.A., Park, M.A., Kang, N.H., Yi, B.R., Hyun, S.H., Jeung, E.B., Choi, K.C., 2013. 
Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 
β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen 
receptor alpha and insulin-like growth factor-1 receptor signaling pathways. Toxicol. 
Appl. Pharmacol. 272, 637–646. https://doi.org/10.1016/j.taap.2013.07.027. 
Hwang, K.A., Park, S.H., Yi, B.R., Choi, K.C., 2011. Gene Alterations of Ovarian Cancer 
Cells Expressing Estrogen Receptors by Estrogen and Bisphenol A Using Microarray 
Analysis. Lab. Anim. Res. 27, 99. https://doi.org/10.5625/lar.2011.27.2.99. 
Idowu, O., Semple, K.T., Ramadass, K., O’Connor, W., Hansbro, P., Thavamani, P., 2019. 
Beyond the obvious: Environmental health implications of polar polycyclic aromatic 
hydrocarbons. Environ. Int. 123, 543–557. https://doi.org/10.1016/j. 
envint.2018.12.051. 
Jenkins, S., Wang, J., Eltoum, I., Desmond, R., Lamartiniere, C.A., 2011. Chronic oral 
exposure to Bisphenol a results in a nonmonotonic dose response in mammary 
carcinogenesis and metastasis in mmtv-erbb2 mice. Environ. Health Perspect. 119, 
1604–1609. https://doi.org/10.1289/ehp.1103850. 
Jones, J.I., Clemmons, D.R., 1995. Insulin-like growth factors and their binding proteins: 
Biological actions. Endocr. Rev. 16, 3–34. https://doi.org/10.1210/edrv-16-1-3. 
Juul, A., 2003. Serum levels of insulin-like growth factor I and its binding proteins in 
health and disease. IGF Res. Growth Horm. 
Kahlert, S., Nuedling, S., Van Eickels, M., Vetter, H., Meyer, R., Grohé, C., 2000. Estrogen 
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